• Je něco špatně v tomto záznamu ?

Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries

M. Kojanova, J. Fialova, P. Cetkovska, S. Gkalpakiotis, J. Jircikova, T. Dolezal, P. Arenberger, . ,

. 2017 ; 56 (4) : 428-434. [pub] 20170209

Jazyk angličtina Země Velká Británie

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016775

BACKGROUND: BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries. METHODS: We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries - DERMBIO, BIOBADADERM, BADBIR, and PSOBEST. RESULTS: A total of 1412 psoriatic patients initiating biological treatment were included with a predominance of males (63.4%). The mean patient age was 50.2 years, and approximately 70.5% of patients were either overweight or obese. The mean baseline Psoriasis Area and Severity Index was 19.8, and the Dermatology Life Quality Index was 16.6. More than one-third of patients (41.0%) reported a history of psoriatic arthritis, and a high proportion of patients (49.5%) with cardiovascular risk factors (hypertension [35.2%], hyperlipidemia [27.7%], diabetes mellitus [11.4%], coronary heart disease [4.9%], and obesity [15.2%]) were observed. Most of the patients had been previously treated with phototherapy (85.4%), acitretin (74.0%), methotrexate (65.7%), or cyclosporine (53.1%). CONCLUSION: BIOREP is one of the first registries of patients with psoriasis treated with biologics in Central and Eastern Europe. Our results found a similar or higher prevalence of comorbidities, long disease duration, and high impact on the quality of life among patients included in Western European registries.

000      
00000naa a2200000 a 4500
001      
bmc18016775
003      
CZ-PrNML
005      
20180516140638.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ijd.13543 $2 doi
035    __
$a (PubMed)28181669
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kojanova, Martina $u Department of Dermatovenereology, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
245    10
$a Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries / $c M. Kojanova, J. Fialova, P. Cetkovska, S. Gkalpakiotis, J. Jircikova, T. Dolezal, P. Arenberger, . ,
520    9_
$a BACKGROUND: BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries. METHODS: We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries - DERMBIO, BIOBADADERM, BADBIR, and PSOBEST. RESULTS: A total of 1412 psoriatic patients initiating biological treatment were included with a predominance of males (63.4%). The mean patient age was 50.2 years, and approximately 70.5% of patients were either overweight or obese. The mean baseline Psoriasis Area and Severity Index was 19.8, and the Dermatology Life Quality Index was 16.6. More than one-third of patients (41.0%) reported a history of psoriatic arthritis, and a high proportion of patients (49.5%) with cardiovascular risk factors (hypertension [35.2%], hyperlipidemia [27.7%], diabetes mellitus [11.4%], coronary heart disease [4.9%], and obesity [15.2%]) were observed. Most of the patients had been previously treated with phototherapy (85.4%), acitretin (74.0%), methotrexate (65.7%), or cyclosporine (53.1%). CONCLUSION: BIOREP is one of the first registries of patients with psoriasis treated with biologics in Central and Eastern Europe. Our results found a similar or higher prevalence of comorbidities, long disease duration, and high impact on the quality of life among patients included in Western European registries.
650    _2
$a acitretin $x terapeutické užití $7 D017255
650    _2
$a dospělí $7 D000328
650    _2
$a biologické přípravky $x terapeutické užití $7 D001688
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a komorbidita $7 D015897
650    _2
$a koronární nemoc $x epidemiologie $7 D003327
650    _2
$a cyklosporin $x terapeutické užití $7 D016572
650    _2
$a Česká republika $x epidemiologie $7 D018153
650    _2
$a dermatologické látky $x terapeutické užití $7 D003879
650    _2
$a diabetes mellitus $x epidemiologie $7 D003920
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hyperlipidemie $x epidemiologie $7 D006949
650    _2
$a hypertenze $x epidemiologie $7 D006973
650    _2
$a keratolytika $x terapeutické užití $7 D007641
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methotrexát $x terapeutické užití $7 D008727
650    _2
$a lidé středního věku $7 D008875
650    _2
$a obezita $x epidemiologie $7 D009765
650    _2
$a fototerapie $7 D010789
650    _2
$a prevalence $7 D015995
650    _2
$a psoriáza $x farmakoterapie $x epidemiologie $x terapie $7 D011565
650    _2
$a kvalita života $7 D011788
650    _2
$a registrace $7 D012042
650    _2
$a opakovaná terapie $7 D019233
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
650    _2
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fialova, Jorga $u Department of Dermatovenereology, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
700    1_
$a Cetkovska, Petra $u Department of Dermatovenereology, Charles University, Faculty of Medicine and University Hospital, Pilsen, Czech Republic.
700    1_
$a Gkalpakiotis, Spyridon $u Department of Dermatovenereology, Charles University, Third Faculty of Medicine and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Jircikova, Jitka $u VALUE OUTCOMES, Prague, Czech Republic.
700    1_
$a Dolezal, Tomas $u VALUE OUTCOMES, Prague, Czech Republic.
700    1_
$a Arenberger, Petr $u Department of Dermatovenereology, Charles University, Third Faculty of Medicine and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a ,
773    0_
$w MED00009891 $t International journal of dermatology $x 1365-4632 $g Roč. 56, č. 4 (2017), s. 428-434
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28181669 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180516140813 $b ABA008
999    __
$a ok $b bmc $g 1300399 $s 1013615
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 56 $c 4 $d 428-434 $e 20170209 $i 1365-4632 $m International journal of dermatology $n Int J Dermatol $x MED00009891
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace